|
gptkbp:instanceOf
|
gptkb:drug
angiotensin II receptor blocker
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:ATCCode
|
C09CA07
|
|
gptkbp:bioavailability
|
42-58%
|
|
gptkbp:brand
|
gptkb:Micardis
|
|
gptkbp:CASNumber
|
144701-48-4
|
|
gptkbp:category
|
gptkb:sartan
antihypertensive agent
|
|
gptkbp:chemicalFormula
|
C33H30N4O2
|
|
gptkbp:combines
|
gptkb:amlodipine
gptkb:hydrochlorothiazide
|
|
gptkbp:contraindication
|
pregnancy
bilateral renal artery stenosis
|
|
gptkbp:discoveredBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:eliminationHalfLife
|
24 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:firstMarketedIn
|
gptkb:Germany
|
|
gptkbp:form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
telmisartan
|
|
gptkbp:interactsWith
|
gptkb:NSAIDs
gptkb:aliskiren
lithium
potassium-sparing diuretics
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:maximumDailyDose
|
80 mg
|
|
gptkbp:mechanismOfAction
|
blocks angiotensin II type 1 receptor
|
|
gptkbp:medlinePlusID
|
a601246
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
514.6 g/mol
|
|
gptkbp:notRecommendedFor
|
children under 18 years
|
|
gptkbp:partOf
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
D (US)
|
|
gptkbp:prescribes
|
adults
|
|
gptkbp:proteinBinding
|
99.5%
|
|
gptkbp:PubChem_CID
|
DB00966
65999
|
|
gptkbp:riskFactor
|
liver dysfunction
hyperkalemia
angioedema
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
hypotension
renal impairment
|
|
gptkbp:UNII
|
U5SYW473RQ
|
|
gptkbp:usedFor
|
hypertension
cardiovascular risk reduction
|
|
gptkbp:bfsParent
|
gptkb:angiotensin_II_receptor_antagonist
gptkb:AT1_receptor
gptkb:angiotensin_receptor_blockers
|
|
gptkbp:bfsLayer
|
7
|